Teva commits to OTC as it winds up alliance

Teva still sees OTC medicines as a “growing and long-term key business”, despite announcing plans with Procter & Gamble (P&G) to end the pair’s six-year ‘PGT Healthcare’ OTC joint venture, according to the Israeli firm. The decision – made after “the companies concluded that their priorities and strategies are no longer closely aligned” – comes as Teva is executing a major structural overhaul instigated by chief executive officer Kåre Schultz (Generics bulletin, 1 December 2017, page 1), and is “not expected to have a material impact on Teva’s 2018 financial outlook”.

Teva still sees OTC medicines as a “growing and long-term key business”, despite announcing plans with Procter & Gamble (P&G) to end the pair’s six-year ‘PGT Healthcare’ OTC joint venture, according to the Israeli firm. The decision – made after “the companies concluded that their priorities and strategies are no longer closely aligned” – comes as Teva is executing a major structural overhaul instigated by chief executive officer Kåre Schultz (Generics bulletin, 1 December 2017, page 1), and is “not expected to have a material impact on Teva’s 2018 financial outlook”.

At the same time, P&G has signed a deal to acquire Merck KGaA’s Consumer Health business for C3.4 billion (US$4.2...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By 

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

Irish Ruling Gives Go-Ahead For Endo-Mallinckrodt Merger

 
• By 

A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

More from Business

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By 

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.